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ㅋ
Constipation, a common problem in gastroenterology practice, may result from slow colonic transit. Therapeutic options for 
slow transit constipations are limited. Excessive methane production by the methanogenic gut flora, which is more often 
found in patients with constipation, slows colonic transit. Thus, reduction in methane production with antibiotic treatment di-
rected against methanogenic flora of the gut may accelerate colonic transit resulting in improvement in constipation. However, 
there is not much data to prove this hypothesis. We, therefore, report a patient with slow transit constipation associated with 
high methane production both in fasting state and after ingestion of glucose, whose constipation improved after treatment 
with non-absorbable antibiotic, rifaximin, which reduced breath methane values.
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Introduction
Chronic constipation, a common problem all over the world, 
may be caused by slow colonic transit. Excessive methane pro-
duction due to presence of methanogenic flora in the gut may 
cause slowing of gut transit.
1 In patients with irritable bowel syn-
drome (IBS), who had excess methane on lactulose hydrogen 
breath test, presence and degree of constipation correlated with 
methane production both subjectively and objectively.
2 In anoth-
er study, methane production after carbohydrate challenge was 
higher in patients with slow transit constipation than in those with 
normal transit, though stool characteristics were similar in both 
groups.
3 Methane production correlated with colonic transit, 
suggesting an association with stool transport but not with stool 
characteristics.
3 In a study of an animal model, infusion of meth-
ane gas into gut slowed down its motility.
4 These data suggested 
that methane gas slowed gut transit, while its effect on stool form 
and consistency was somewhat contradictory. Moreover, there is 
no data on the use of methane-reducing drugs that modulate gut 
flora and their effect on colonic transit and stool form. We report 
a patient with slow transit constipation associated with excess Uday C Ghoshal, et al
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Figure. Effect of rifaximin on stool form and frequency, breath methane and colonic transit as assessed by radio-opaque markers in a patient with
slow transit constipation associated with high breath methane in fasting state and following ingestion of 100 g glucose (left panel: before treatment;
right panel: after rifaximin). The patient also had a diminutive polyp in rectum on colonoscopy (indicated by arrow). 
methane production; her stool form and frequency improved af-
ter reduction of methane production using gut specific antibiotic, 
which also accelerated colonic transit.
Case Report
A 57-year old female presented to us with constipation, 
post-prandial epigastric fullness, tiredness, nausea and belching. 
These symptoms were present for more than 15 years without any 
significant change in severity. She used to pass stool every 2 to 3 
days and had feeling of incomplete evacuation. Stools were hard, 
lumpy, which were difficult to pass (Bristol type I, Figure).
5 She 
denied evacuating manually or having rectal prolapse. Alarm fea-
tures such as unintentional weight loss, bleeding per rectum, se-
vere abdominal pain and anorexia were absent. There was no 
family history of colonic malignancy. She did not have vomiting. 
She had 4 children and underwent hysterectomy 20 years ago for 
symptomatic fibroid. She underwent surgical treatment for left 
para-sellar cavernous hemangioma 6 months ago. Laboratory 
findings revealed mild anemia (hemoglobin 10.0 g/dL), fasting 
blood sugar 88 mg/dL, serum creatinine 0.7 mg/ dL, serum al-
bumin 4.0 g/dL and normal thyroid stimulating hormone level 
(2.82 mIU/L). Colonoscopy showed a diminutive polyp in rec-
tum, which was a hyperplastic polyp on histology (Figure). 
Colonic transit time using a previously validated protocol (20 
markers each at 0, 12 and 24 hour; abdominal radiographs at 36 
and 60 hour) showed 54 of 60 markers retained at 60 hour 
(abnormal > 14 markers) suggestive of slow colonic transit 
(Figure).
6 Radionuclide gastric emptying study using technetium 
99-m sulfur colloid labeled standard solid meal showed clearance 
half time of 61 minutes (normal 83 ± 13 minutes).
7 Glucose hy-
drogen breath test using a standard protocol (Quin Tron Brea-
thtracker
TM Digital Microlyzer, QuinTron Inc, Milwaukee, 
WI, USA) revealed rise in breath hydrogen from 13 parts per Rifaximin Improves Slow Transit Constipation
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million (ppm) in fasting state to 36 ppm after ingestion of 100 g 
glucose (abnormal > 12 ppm than basal) suggesting small in-
testinal bacterial overgrowth (Figure; sensitivity 44% and specif-
icity 80%).
8 She had high methane excretion in breath (50 ppm) 
both in fasting state and after ingestion of glucose suggesting 
presence of methane producing bacteria in the gut (Figure). 
Since methane is known to reduce gut transit that may result in 
constipation, she was treated with rifaximin 1,200 mg per day in 3 
divided doses for 14 days to reduce methane in her gut. Her 
symptoms improved with stool frequency of 1 per day of Bristol 
type IV without laxative and enema (Figure). CTT was repeated 
to reassess colonic transit, which showed 30 of 60 markers re-
tained after 60 hours (Figure). Glucose hydrogen breath test re-
peated after 2 weeks did not show small intestinal bacterial over-
growth and methane excretion in breath was low (< 5 ppm, Fi
gure). At this stage, she was prescribed with low-dose tegaserod, 
which is known to prevent recurrence of symptoms following 
treatment directed to small intestinal bacterial overgrowth.
9 She 
remained well during 2-month follow-up.
Discussion
Our patient had slow-transit constipation as evidenced by 
stool frequency less than 3 per week, hard stools (Bristol type I), 
need for laxative and enema with retention of 54 of 60 markers at 
60 hour abdominal radiograph. She had high quantity of methane 
in exhaled air both at fasting state and after ingestion of glucose. 
We hypothesized that high amount of methane could slow down 
her gut transit causing constipation; association between high 
breath methane and slow colonic transit resulting in constipation 
has been described in literature. Our hypothesis was further sup-
ported by improvement of colonic transit and consequent im-
provement in stool frequency and form after reduction in meth-
ane excretion by treatment with rifaximin.
Methane production in the gut is known to be associated 
with slow gut transit. Previous studies showed that methane pro-
duction in IBS patients was almost universally associated with 
constipation and lumpy stools.
2,10 In contrast, patients with diar-
rhea usually have higher excretion of hydrogen in breath both 
during fasting state and following administration of glucose.
11,12 
Methane was associated with presence and degree of constipation 
both subjectively and objectively in a study on 87 IBS patients, 20 
(24%) of whom produced methane on lactulose hydrogen breath 
test.
2 In another study, methane production after carbohydrate 
challenge correlated with colonic transit but not with stool 
characteristics.
3 The mechanism of slow colonic transit due to ex-
cess methane in the gut might be related to abnormality in in-
testinal motility and reduction in serotonin production. 
Our patient had slow transit constipation and excess methane 
production both in fasting state and following challenge with 
glucose. Slow colonic transit and constipation in our patient 
might result from excess methane gas in her gut as both con-
stipation and colonic transit improved after reduction of methane 
gas with treatment of rifaximin. Recently, in 2 identically de-
signed phase 3, double-blind, placebo-controlled trials, IBS pa-
tients without constipation, treatment with rifaximin for 2 weeks 
provided significant relief of IBS symptoms, bloating, abdominal 
pain, and loose or watery stools.
13 However, the present case sug-
gests that even constipation resulting from slow motility due to 
excess methane production may improve after treatment with 
rifaximin.
In conclusion, the present case report suggests that con-
stipation resulting from slow transit due to excess methane pro-
duction in gut may respond to treatment with antibiotics such as 
rifaximin, which reduces methane production by reducing the 
methanogenic flora in the gut. Further study in the form of a 
randomized controlled trial is required to substantiate this 
finding.
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